Injective, a notable player in the crypto space, has just wrapped up a significant technical transition: the migration of its INJ token from Ethereum’s ERC-20 standard to a native version on its own blockchain, the Injective EVM. This shift, completed by July 22, 2026, marks a major step for the platform’s ecosystem, with Coinbase leading the charge in supporting this new format over its predecessor.
The transition, which started on July 20, allowed Coinbase users to experience a seamless 1:1 conversion of their holdings. Post-migration, you can now trade directly on the native Injective network, effectively making the ERC-20 version a relic of the past. Coinbase’s decision to end its support for ERC-20 INJ deposits and withdrawals emphasizes this new chapter for the token.
What’s the big deal with the migration?
This isn’t just a switch for tech’s sake. The move to the native Injective EVM chain means better access to decentralized finance (DeFi) applications and increased liquidity for users. If you’ve ever been frustrated with cross-chain compatibility and transaction times, this development might just make your day.
Injective has been laying the groundwork for this since its native EVM launched back in November 2025. The migration aligns with a series of strategic moves, including a partnership with Robinhood, which could make Injective’s offerings accessible to a broader audience. These were highlighted at the Injective Summit in Washington, D.C., last month.
Why investors should be paying attention
Let’s talk money. For investors, the implications are clear: streamlined technology often paves the way for an increase in user engagement and transaction volume. This could positively affect INJ’s market performance, injecting a jolt of enthusiasm into its price trajectory.
The combined support from platforms like Coinbase and Robinhood offers a nod of credibility and could attract more institutional interest. So, expect the usual suspects in the market—like improved liquidity and heightened trading activity—to play their part in shaping INJ’s future.
Optimists in the market view this as a chance for Injective to increase its footprint. With enhanced technical capabilities and more robust user engagement, the blockchain aims to stand out in an increasingly crowded DeFi space.
Anticipating the next moves
While it’s too early to build castles in the sky about INJ’s potential valuation jumps, aligning strategic improvements with increased adoption often spells good news. As traders transition from the old ERC-20 standard, any uptick in liquidity could have investors hitting the buy button.
Naturally, there are risks. Technological transitions come with their own set of challenges and uncertainties. Yet, the early signs from the migration suggest that Injective is on a solid path toward cementing its position as a DeFi leader.